Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in the Phase 3 Clinical Trials in Psoriasis, POETYK PSO-1 and PSO-2: Time to Meaningful Improvements in Itch as Assessed by the Psoriasis Symptoms and Signs Diary. J of Skin [Internet]. 2024 Mar. 18 [cited 2025 Apr. 4];8(2):s358. Available from: https://skin.dermsquared.com/skin/article/view/2653